WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573920
Description: JM-221 is a novel platinum(IV) dicarboxylate complex exhibiting enhanced cytotoxicity in human ovarian carcinoma cell line when compared to Cisplatin. Comparison with platinum accumulation from Cisplatin suggests that the increased cytotoxicity of JM-221 may be related to increased accumulation within the cell. JM-221 is more lipophilic than Cisplatin, which may account for improved uptake in Cisplatin resistant cells.
MedKoo Cat#: 573920
Chemical Formula: C14H30Cl2N2O4Pt
Exact Mass: 555.123
Molecular Weight: 556.39
Elemental Analysis: C, 30.22; H, 5.44; Cl, 12.74; N, 5.03; O, 11.50; Pt, 35.06
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JM-221, JM 221, JM221
IUPAC/Chemical Name: Platinum, amminebis(butanoato-O)dichloro(cyclohexanamine)-, (OC-6-43)-
InChi Key: XMOWMXXEICQRQH-UHFFFAOYSA-J
InChi Code: 1S/C6H13N.2C4H8O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2-3-4(5)6;;;;/h6H,1-5,7H2;2*2-3H2,1H3,(H,5,6);2*1H;1H3;/q;;;;;;+4/p-4
SMILES Code: [O-]C(CCC)=O.[O-]C(=O)CCC.C1CCCC(C1)N.[ClH-].N.[ClH-].[Pt+4]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 556.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br J Cancer. 1994 Sep;70(3):415-20. PubMed PMID: 8080724; PubMed Central PMCID: PMC2033379.
2: McKeage MJ, Abel G, Kelland LR, Harrap KR. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. Br J Cancer. 1994 Jan;69(1):1-7. PubMed PMID: 8286188; PubMed Central PMCID: PMC1968778.
3: Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 1993 Aug;68(2):240-50. PubMed PMID: 8347478; PubMed Central PMCID: PMC1968570.
4: Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992 Feb 15;52(4):822-8. PubMed PMID: 1737343.